Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Accumulated Expenses (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Other Accumulated Expenses data on record, last reported at $400000.0 in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 39900.0% year-over-year to $400000.0; the TTM value through Dec 2025 reached $400000.0, up 39900.0%, while the annual FY2025 figure was $400000.0, 39900.0% up from the prior year.
  • Other Accumulated Expenses reached $400000.0 in Q4 2025 per FHTX's latest filing, up from $396000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $526000.0 in Q1 2025 and bottomed at $1000.0 in Q4 2024.
  • Average Other Accumulated Expenses over 5 years is $257470.6, with a median of $272000.0 recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: crashed 97.22% in 2024, then skyrocketed 39900.0% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $392000.0 in 2021, then fell by 18.88% to $318000.0 in 2022, then plummeted by 88.68% to $36000.0 in 2023, then plummeted by 97.22% to $1000.0 in 2024, then surged by 39900.0% to $400000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $400000.0 in Q4 2025, $396000.0 in Q3 2025, and $392000.0 in Q2 2025.